Jove
Visualize
Contact Us

Related Experiment Videos

Cognitive function in schizophrenia--do neuroleptics make a difference?

A M Mortimer1

  • 1Postgraduate Medical School, University of Hull, UK.

Pharmacology, Biochemistry, and Behavior
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on the Royal College of Radiologists sponsored credential Mechanical Thrombectomy for Acute Ischaemic Stroke: thoughts about implementation in an under-resourced environment.

Clinical radiology·2023
Same author

Carryover effects on the clonal growth of the grass Holcus lanatus L.

The New phytologist·2021
Same author

Electroencephalographic (EEG) features of encephalopathy in the setting of Covid-19: A case series.

Clinical neurophysiology practice·2020
Same author

Anaesthetic preferences for endovascular stroke thrombectomy.

Anaesthesia·2020
Same author

Spinal dural arteriovenous fistula: delay to radiological diagnosis and sources of radiological error.

Clinical radiology·2018
Same author

DIVERGENCE AND GENETIC STRUCTURE IN ADJACENT GRASS POPULATIONS. I. QUANTITATIVE GENETICS.

Evolution; international journal of organic evolution·2017
Same journal

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior·2026
Same journal

Modulation of prefrontal NMDA receptors reveals pharmacogenetic differences between SHR and SLA16 rat strains.

Pharmacology, biochemistry, and behavior·2026
Same journal

Spontaneous oxycodone withdrawal alters behavior and oligodendrocyte-related gene expression in mice.

Pharmacology, biochemistry, and behavior·2026
Same journal

Improvement in depressive symptoms in people undergoing cognitive behavioral therapy who supplemented with probiotics: An open-label, pilot study.

Pharmacology, biochemistry, and behavior·2026
Same journal

Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol.

Pharmacology, biochemistry, and behavior·2026
Same journal

Fluoxetine reduces anxiety-like behavior but increases motor impairments in the early stages of a progressive model of Parkinson's disease.

Pharmacology, biochemistry, and behavior·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Cognitive deficits in schizophrenia are significant and not explained by other factors. While conventional neuroleptics show minor effects, newer atypical antipsychotics may offer potential for cognitive remediation in schizophrenia patients.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cognitive Psychology

Background:

  • Schizophrenia is characterized by significant cognitive deficits, particularly in memory and executive functions.
  • These deficits impact theoretical models and patient outcomes, and are not explained by symptomatology or institutionalization.
  • Neuroleptic medications interact with brain arousal systems, potentially affecting cognition.

Purpose of the Study:

  • To review the impact of neuroleptic treatments on cognitive function in schizophrenia.
  • To explore the potential of atypical neuroleptics to remediate cognitive impairment.
  • To identify needs for future research methodology.

Main Methods:

  • Literature review of studies on neuroleptics and cognition in schizophrenia.

Related Experiment Videos

  • Analysis of the effects of conventional versus atypical neuroleptics.
  • Discussion of methodological considerations for future research.

    • Main Results:

    • Conventional neuroleptics have minor effects on schizophrenia cognition.
    • Atypical neuroleptics, like clozapine, show potential for cognitive sparing, but further research is needed.
    • Current methodologies may be insufficient for robust evaluation.

    Conclusions:

    • Atypical neuroleptics may offer a promising avenue for improving cognitive function in schizophrenia.
    • Further hypothesis-driven research with advanced methodology is crucial.
    • Improved patient evaluation and real-life applicability are needed for future studies.